Location: Palo Alto, CA
CIK: 0001674712 · Show all filings
Period: Q4 2025 (← Previous) (Next →)
Filing Date: Feb 13, 2026
Total Value: $1.547B (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| TERN | Terns Pharmaceuticals Inc | 5,346,928 | $216M | 14.0% | $11.04 | +109.3% | Common | 880881107 |
| — | Cidara Therapeutics, Inc. | 956,670 | $211M | 13.7% | $37.26 | — | Common | 171757206 |
| PRAX | Praxis Precision Medicines | 328,895 | $96.94M | 6.3% | $97.63 | +90.8% | Common | 74006W207 |
| COGT | Cogent Biosciences Inc | 2,398,993 | $85.21M | 5.5% | $10.52 | +167.2% | Common | 19240Q201 |
| TRVI | Trevi Therapeutics Inc | 5,094,668 | $63.79M | 4.1% | $4.23 | +173.0% | Common | 89532M101 |
| — | Avadel Pharmaceuticals PLC | 2,684,109 | $57.84M | 3.7% | $13.12 | — | ADR | G29687103 |
| CMPX | Compass Therapeutics Inc | 9,545,466 | $51.26M | 3.3% | $3.04 | +52.1% | Common | 20454B104 |
| DYN | Dyne Therapeutics Inc | 2,614,960 | $51.15M | 3.3% | $14.50 | +30.6% | Common | 26818M108 |
| ABVX | Abivax SA - ADR | 359,305 | $48.45M | 3.1% | $84.90 | — | SPONSORED ADS | 00370M103 |
| DBVT | DBV Technologies SA | 2,461,626 | $47.19M | 3.1% | $14.88 | — | SPONSORED ADS | 23306J309 |
| SABS | SAB Biotherapeutics Inc | 11,420,000 | $42.71M | 2.8% | $2.26 | +45.5% | Common | 78397T202 |
| SLNO | Soleno Therapeutics Inc | 894,909 | $41.43M | 2.7% | $19.93 | +175.1% | Common | 834203309 |
| DRUG | Bright Minds Biosciences Inc | 501,617 | $39.15M | 2.5% | $37.00 | +80.6% | Common | 10919W405 |
| SVA | Sinovac Biotech Ltd. | 5,903,000 | $38.19M | 2.5% | $6.47 | 0.0% | SHS | P8696W104 |
| GERN | Geron Corp | 27,225,292 | $35.94M | 2.3% | $1.62 | -22.4% | Common | 374163103 |
| ERAS | Erasca Inc | 9,273,428 | $34.5M | 2.2% | $2.00 | +40.3% | Common | 29479A108 |
| ZBIO | Zenas Biopharma Inc | 853,495 | $30.99M | 2.0% | $17.98 | +82.9% | Common | 98937L105 |
| VRDN | Viridian Therapeutics Inc | 982,576 | $30.58M | 2.0% | $15.47 | +77.3% | Common | 92790C104 |
| ACRS | Aclaris Therapeutics, Inc. | 8,888,888 | $26.76M | 1.7% | $2.49 | +1.6% | Common | 00461U105 |
| CAMP | CAMP4 Therapeutics Inc | 4,246,568 | $26.03M | 1.7% | $2.04 | +109.0% | Common | 13463J101 |
| TNGX | Tango Therapeutics Inc | 2,154,780 | $19.09M | 1.2% | $6.75 | +27.6% | Common | 87583X109 |
| ANRO | Alto Neuroscience Inc | 1,035,551 | $18.43M | 1.2% | $12.59 | 0.0% | Common | 02157Q109 |
| LBRX | LB Pharmaceuticals Inc | 800,000 | $17.81M | 1.2% | $15.87 | +10.1% | Common | 50180M108 |
| NERV | Minerva Neurosciences Inc | 4,322,747 | $17.38M | 1.1% | $3.71 | 0.0% | Common | 603380205 |
| ORIC | Oric Pharmaceuticals Inc | 2,118,384 | $17.33M | 1.1% | $7.92 | +45.3% | Common | 68622P109 |
| CRVS | Corvus Pharmaceuticals Holdings | 2,234,566 | $17.21M | 1.1% | $4.87 | +62.0% | Common | 221015100 |
| OLMA | Olema Pharmaceuticals Inc | 671,843 | $16.8M | 1.1% | $31.43 | -43.4% | Common | 68062P106 |
| PEPG | Pepgen Inc | 2,325,000 | $15.14M | 1.0% | $1.61 | +222.0% | Common | 713317105 |
| DSGN | Design Therapeutics Inc | 1,612,903 | $15.13M | 1.0% | $7.83 | 0.0% | Common | 25056L103 |
| DNTH | Dianthus Therapeutics Inc | 353,998 | $14.59M | 0.9% | $25.56 | +51.7% | Common | 252828108 |
| MLTX | Moonlake Immunotherapeutics | 1,000,000 | $13.18M | 0.9% | $11.80 | 0.0% | Common | 61559X104 |
| CTMX | Cytomx Therapeutics Inc | 2,884,615 | $12.29M | 0.8% | $1.61 | +135.7% | Common | 23284F105 |
| UNCY | Unicycive Therapeutics | 1,789,916 | $10.33M | 0.7% | $5.52 | -3.2% | Common | 90466Y202 |
| EPRX | Eupraxia Pharmaceuticals Inc | 1,350,000 | $10.19M | 0.7% | $5.44 | +13.3% | Common | 29842P105 |
| ABEO | Abeona Therapeutics, Inc. | 1,842,751 | $9.711M | 0.6% | $5.10 | -1.3% | Common | 00289Y206 |
| VSTM | Verastem Inc | 1,106,524 | $8.542M | 0.6% | $7.15 | +24.6% | Common | 92337C203 |
| SLN | Silence Therapeutics PLC | 1,105,454 | $6.721M | 0.4% | $19.65 | — | ADS | 82686Q101 |
| MNPR | Monopar Therapeutics Inc | 90,500 | $5.91M | 0.4% | $44.70 | +82.8% | Common | 61023L207 |
| SRZN | Surrozen Inc | 260,000 | $5.876M | 0.4% | $11.62 | +39.2% | Common | 86889P208 |
| PALI | Palisade Bio Inc | 2,293,578 | $5.39M | 0.3% | $1.92 | 0.0% | Common | 696389402 |
| SERA | Sera Prognostics Inc | 1,650,440 | $4.869M | 0.3% | $10.38 | -68.9% | Common | 81749D107 |
| TIL | Instil Bio Inc | 292,743 | $3.22M | 0.2% | $7.23 | +104.5% | Common | 45783C200 |
| KTTA | Pasithea Therapeutics Corp | 2,100,000 | $2.709M | 0.2% | $0.88 | 0.0% | Common | 70261F202 |
| TENX | Tenax Therapeutics Inc | 208,333 | $2.54M | 0.2% | $3.62 | +140.2% | Common | 88032L605 |
| ENGNW | EnGene Holdings Inc | 285,046 | $844K | 0.1% | $2.96 | — | Warrants | 29286M113 |
| BOLT | Bolt Therapeutics Inc | 72,414 | $396K | 0.0% | $6.62 | -18.9% | Common | 097702203 |
| DTIL | Precision Biosciences Inc | 4,675 | $19,449 | 0.0% | $12.24 | -53.6% | Common | 74019P207 |